Coeptis Therapeutics Holdings Inc
COEP14.660USD
+0.020+0.14%
收盘 12/19, 16:00（美东）报价延迟15分钟
75.61M总市值
亏损市盈率 TTM
关于 Coeptis Therapeutics Holdings Inc 公司
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc简介
公司代码COEP
公司名称Coeptis Therapeutics Holdings Inc
上市日期Dec 17, 2020
CEOMehalick (David)
员工数量5
证券类型Ordinary Share
年结日Dec 17
公司地址105 Bradford Road, Suite 420
城市WEXFORD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编15090
电话17249346467
网址https://coeptistx.com/
公司代码COEP
上市日期Dec 17, 2020
CEOMehalick (David)
Coeptis Therapeutics Holdings Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月20日 周四
更新时间: 11月20日 周四
持股股东
股东类型
持股股东
持股股东
占比
Calise (Chris)
5.86%
Mehalick (David)
2.44%
Armistice Capital LLC
1.77%
The Vanguard Group, Inc.
0.95%
Sheehy (Christine Elise)
0.95%
其他
88.04%
持股股东
持股股东
占比
Calise (Chris)
5.86%
Mehalick (David)
2.44%
Armistice Capital LLC
1.77%
The Vanguard Group, Inc.
0.95%
Sheehy (Christine Elise)
0.95%
其他
88.04%
股东类型
持股股东
占比
Individual Investor
10.17%
Hedge Fund
2.12%
Investment Advisor/Hedge Fund
1.22%
Investment Advisor
1.18%
其他
85.31%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
36
241.64K
3.38%
--
2025Q3
37
241.64K
3.76%
+42.71K
2025Q2
35
198.94K
3.83%
+46.67K
2025Q1
35
152.27K
2.68%
+61.98K
2024Q4
37
107.84K
11.51%
-74.49K
2024Q3
50
182.34K
16.17%
+98.47K
2024Q2
52
83.87K
26.32%
-153.34K
2024Q1
74
237.20K
33.65%
-370.03K
2023Q4
75
236.65K
31.22%
+72.09K
2023Q3
78
164.55K
39.28%
-2.06K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Calise (Chris)
312.69K
6.49%
--
--
Sep 11, 2025
Mehalick (David)
130.07K
2.7%
--
--
Sep 11, 2025
Armistice Capital LLC
94.77K
1.97%
+94.77K
--
Sep 30, 2024
The Vanguard Group, Inc.
27.53K
0.57%
+3.09K
+12.65%
Jun 30, 2025
Sheehy (Christine Elise)
50.53K
1.05%
--
--
Sep 11, 2025
Yerace (Daniel Alexander)
45.53K
0.94%
-5.00K
-9.89%
Sep 11, 2025
Geode Capital Management, L.L.C.
20.28K
0.42%
+311.00
+1.56%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
公告日期
类型
比率
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
常见问题
Coeptis Therapeutics Holdings Inc的前五大股东是谁？
Coeptis Therapeutics Holdings Inc 的前五大股东如下：
Calise (Chris)持有股份：312.69K，占总股份比例：6.49%。
Mehalick (David)持有股份：130.07K，占总股份比例：2.70%。
Armistice Capital LLC持有股份：94.77K，占总股份比例：1.97%。
The Vanguard Group, Inc.持有股份：27.53K，占总股份比例：0.57%。
Sheehy (Christine Elise)持有股份：50.53K，占总股份比例：1.05%。
Calise (Chris)持有股份：312.69K，占总股份比例：6.49%。
Mehalick (David)持有股份：130.07K，占总股份比例：2.70%。
Armistice Capital LLC持有股份：94.77K，占总股份比例：1.97%。
The Vanguard Group, Inc.持有股份：27.53K，占总股份比例：0.57%。
Sheehy (Christine Elise)持有股份：50.53K，占总股份比例：1.05%。
Coeptis Therapeutics Holdings Inc的前三大股东类型是什么？
Coeptis Therapeutics Holdings Inc 的前三大股东类型分别是：
Calise (Chris)
Mehalick (David)
Armistice Capital LLC
Calise (Chris)
Mehalick (David)
Armistice Capital LLC
有多少机构持有Coeptis Therapeutics Holdings Inc(COEP)的股份？
截至2025Q4，共有36家机构持有Coeptis Therapeutics Holdings Inc的股份，合计持有的股份价值约为241.64K，占公司总股份的3.38%。与2025Q3相比，机构持股有所增加，增幅为-0.38%。
哪个业务部门对Coeptis Therapeutics Holdings Inc的收入贡献最大？
在--，--业务部门对Coeptis Therapeutics Holdings Inc的收入贡献最大，创收--，占总收入的--%。
